Keryx Biopharmaceuticals has announced that its new drug application (NDA) for Zerenex (ferric citrate coordination complex) has been accepted for filing by the US FDA.
Keryx’s NDA for kidney drug accepted for filing by US FDA
Zerenex aims to lower blood levels of phosphorous in patients undergoing kidney dialysis.